Rapport Therapeutics (RAPP) Cash from Financing Activities (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Cash from Financing Activities data on record, last reported at $531000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 10520.0% to $531000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $271.3 million, a 71.75% increase, with the full-year FY2025 number at $270.8 million, up 22.18% from a year prior.
- Cash from Financing Activities reached $531000.0 in Q1 2026 per RAPP's latest filing, up from $311000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for RAPP hit a ceiling of $270.5 million in Q3 2025 and a floor of -$1.4 million in Q3 2024.
- A 4-year average of $52.6 million and a median of $311000.0 in 2025 define the central range for Cash from Financing Activities.
- Peak YoY movement for Cash from Financing Activities: plummeted 101.63% in 2024, then skyrocketed 19506.96% in 2025.
- Tracing RAPP's Cash from Financing Activities over 4 years: stood at -$140000.0 in 2023, then soared by 105.0% to $7000.0 in 2024, then skyrocketed by 4342.86% to $311000.0 in 2025, then surged by 70.74% to $531000.0 in 2026.
- Business Quant data shows Cash from Financing Activities for RAPP at $531000.0 in Q1 2026, $311000.0 in Q4 2025, and $270.5 million in Q3 2025.